Benefit/risk of therapies for rheumatoid arthritis: Underestimation of the "side effects" or risks of RA leads to underestimation of the benefit/risk of therapies

Clinical and Experimental Rheumatology

Volumn 22, Issue 5 SUPPL. 35, 2004, Pages

  Pincus, Theodore ^a   Kavanaugh, A ^b   Sokka, T ^a,c  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c JYVÄSKYLÄ CENTRAL HOSPITAL   (Finland)

Author keywords

Benefit; Rheumatoid arthritis; Risks; Side effects; Therapy

Indexed keywords

ADALIMUMAB; ANTIRHEUMATIC AGENT; AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; ETANERCEPT; GOLD SALT; HYDROXYCHLOROQUINE; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLAMINE; PREDNISOLONE; PREDNISONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; SALAZOSULFAPYRIDINE; BIOLOGICAL PRODUCT; CYCLOSPORIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG;

BLADDER DISEASE; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; DIABETES MELLITUS; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; DRUG RESEARCH; DRUG USE; GASTROINTESTINAL DISEASE; HEMATOLOGIC DISEASE; HODGKIN DISEASE; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; KIDNEY DISEASE; LIVER DISEASE; LONGITUDINAL STUDY; LYMPHOMA; MORTALITY; NEOPLASM; OSTEOPENIA; POPULATION RESEARCH; PREDICTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RETINOPATHY; REVIEW; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; TERATOGENICITY; TREATMENT OUTCOME; TUBERCULOSIS; ARTICLE; BONE DENSITOMETRY; DISABILITY; GRIP STRENGTH; HEALTH ASSESSMENT QUESTIONNAIRE; JOINT DESTRUCTION; MORTALITY RATE; POLYARTHRITIS; PREMATURE MORTALITY; RETINA DISEASE; WORK DISABILITY;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; HUMANS; RISK ASSESSMENT;

EID: 4944258175     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (159)

1. KELLEY WN, HARRIS ED Jr, RUDDY S, SLEDGE CB: Textbook of Rheumatology. 2nd ed., Philadelphia, W.B. Saunders, 1985: 979.
2. LIGHTFOOT RW Jr: Treatment of rheumatoid arthritis. In McCARTY DJ (Ed.): Arthritis and Allied Conditions. Philadelphia, Lea & Febiger, 1985: 668-76.
3. THOULD AK, SIMON G: Assessment of radiological changes in the hands and feet in rheumatoid arthritis: their correlation with prognosis. Ann Rheum Dis 1966; 25: 220-8.
4. BROOK A, CORBETT M: Radiographic changes in early rheumatoid disease. Ann Rheum Dis 1977; 36: 71-3.
5. SCOTT DL, COULTON BL, BACON PA, POPERT AJ: Methods of x-ray assessment in rheumatoid arthritis: A re-evaluation. Br J Rheumatol 1985; 24: 31-9.
6. FUCHS HA, KAYE JJ, CALLAHAN LF, NANCE EP, PINCUS T: Evidence of significant radiographic damage in rheumatoid arthritis within the first 2 years of disease. J Rheumatol 1989; 16: 585-91.
7. SALAFFI F, FERRACCIOLI GF: Progress of the anatomical damage in rheumatoid hands. Radiography of the natural course of the disease or of the course during treatment? Scand J Rheumatol 1989; 18: 119-20.
8. SHARP JT: Scoring radiographic abnormalities in rheumatoid arthritis. J Rheumatol 1989; 16:568-9.
9. PINCUS T, CALLAHAN LF, SALE WG, BROOKS AL, PAYNE LE, VAUGHN WK: Severe functional declines, work disability, and increased mortality in seventy-five rheumatoid arthritis patients studied over nine years. Arthritis Rheum 1984; 27: 864-72.
10. SHERRER YS, BLOCH DA, MITCHELL DM, YOUNG DY, FRIES JF: The development of disability in rheumatoid arthritis. Arthritis Rheum 1986: 29: 494-500.
11. WOLFE F, HAWLEY DJ, CATHEY MA: The risk of functional disability and the rate of its development in patients with rheumatoid arthritis. Arthritis Rheum 1989; 32: S88.
12. YELIN E, MEENAN R, NEVITT M, EPSTEIN W: Work disability in rheumatoid arthritis: effects of disease, social, and work factors. Ann Intern Med 1980; 93: 551-6.
13. MITCHELL JM, BURKHAUSER RV, PINCUS T: The importance of age, education, and comorbidity in the substantial earnings losses of individuals with symmetric polyarthritis. Arthritis Rheum 1988; 31: 348-57.
14. MÄKISARA GL, MÄKISARA P: Prognosis of functional capacity and work capacity in rheumatoid arthritis. Clin Rheumatol 1982; 1: 117-25.
15. PINCUS T, CALLAHAN LF: Taking mortality in rheumatoid arthritis seriously - predictive markers, socioeconomic status and comorbidity. J Rheumatol 1986; 13:841-5.
16. MITCHELL DM, SPITZ PW, YOUNG DY, BLOCH DA, McSHANE DJ, FRIES JF: Survival, prognosis, and causes of death in rheumatoid arthritis. Arthritis Rheum 1986; 29: 706-14.
17. PINCUS T, CALLAHAN LF, VAUGHN WK: Questionnaire, walking time and button test measures of functional capacity as predictive markers for mortality in rheumatoid arthritis. J Rheumatol 1987; 14: 240-51.
18. MUTRU O, LAAKSO M, ISOMÄKI H, KOOTA K: Ten year mortality and causes of death in patients with rheumatoid arthritis. Br Med J 1985; 290: 1811-3.
19. WOLFE F, HAWLEY DJ, CATHEY MA: Termination of slow acting anti-rheumatic therapy in rheumatoid arthritis: A 14-year prospective evaluation of 1017 consecutive starts. J Rheumatol 1990; 17: 994-1002.
20. PINCUS T, MARCUM SB, CALLAHAN LF: Long-term drug therapy for rheumatoid arthritis in seven rheumatology private practices. II. Second-line drugs and prednisone. J Rheumatol 1992; 19: 1885-94.
21. WEINBLATT ME, COBLYN JS, FOX DA et al.: Efficacy of low-dose methotrexate in rheumatoid arthritis. N Engl J Med 1985; 312: 818-22.
22. KRAUSE D, SCHLEUSSER B, HERBORN G, RAU R: Response to methotrexate treatment is associated with reduced mortality in patients with severe rheumatoid arthritis. Arthritis Rheum 2000; 43: 14-21.
23. CHOI HK, HERNÁN MA, SEEGER JD, ROBINS JM, WOLFE F: Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 2002; 359: 1173-7.
24. MIESCHER PA, FAVRE H, MIHATSCH MJ, CHATELANAT F, HUANG YP, ZUBLER R: The place of cyclosporine A in the treatment of connective tissue diseases. Transplant Proc 1988; 20: 224-37.
25. SMOLEN JS, KALDEN JR, SCOTT DL et al.: Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: A double-blind, randomised, multicentre trial. Lancet 1999; 353: 259-66.
26. STRAND V, COHEN S, SCHIFF M et al.: Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Arch Intern Med 1999; 159: 2542-50.
27. MORELAND LW, BAUMGARTNER SW, SCHIFF MH et al.: Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997; 337: 141-7.
28. WEINBLATT ME, KREMER JM, BANKHURST AD et al.: A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999;340: 253-9.
29. MAINI RN, BREEDVELD FC, KALDEN JR et al.: Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998; 41:1552-63.
30. LIPSKY PE, VAN DER HEIJDE DMFM, St CLAIR EW et al.: Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000; 343: 1594-602.
31. WEINBLATT ME, KEYSTONE EC, FURST DE et al.: Adalimumab, a fully human anti-tumor necrosis factor a monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003; 48: 35-45.
32. VAN DE PUTTE LBA, RAU R, BREEDVELD FC et al.: Efficacy and safety of fully human anti-tumour necrosis factor a monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study. Ann Rheum Dis 2003; 62: 1168-77.
33. BRESNIHAN B, ALVARO-GRACIA JM, COBBY M et al.: Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum 1998; 41:2196-204.
34. DAYER JM: Evidence for the biological modulation of IL-1 activity: role of IL-1Ra. Clin Exp Rheumatol 2002; 20 (Suppl. 27): S14-20.
35. PINCUS T, CALLAHAN LF: Reassessment of twelve traditional paradigms concerning the diagnosis, prevalence, morbidity and mortality of rheumatoid arthritis. Scand J Rheumatol 1989; 18 (Suppl. 79): 67-96.
36. WILSKE KR, HEALEY LA: Remodeling the pyramid - a concept whose time has come. J Rheumatol 1989; 16: 565-7.
37. FRIES JF: Re-evaluating the therapeutic approach to rheumatoid arthritis: the "sawtooth" strategy. J Rheumatol 1990; 17 (Suppl. 22): 12-5.
38. PINCUS T, CALLAHAN LF: Remodeling the pyramid or remodeling the paradigms concerning rheumatoid arthritis - lessons from Hodgkin's disease and coronary artery disease. J Rheumatol 1990; 17: 1582-5.
39. McCARTY DJ: Suppress rheumatoid inflammation early and leave the pyramid to the Egyptians. J Rheumatol 1990; 17: 1115-8.
40. KLIPPEL JH: Comment: Winning the battle, losing the war? Another editorial about RA. J Rheumatol 1990; 17: 1118-22.
41. BENSEN WG, BENSEN W, ADACHI JD, TUGWELL P: Remodeling the pyramid: The therapeutic target of RA. J Rheumatol 1990; 17:987-9.
42. PINCUS T: The paradox of effective therapies but poor long-term outcomes in rheumatoid arthritis. Semin Arthritis Rheum 1992; 21: 2-15.
43. PINCUS T: Rheumatoid arthritis: A medical emergency? Scand J Rheumatol 1994; 23(Suppl. 100): 21-30.
44. EMERY P, SALMON M: Early rheumatoid arthritis: time to aim for remission? Ann Rheum Dis 1995; 54: 944-7.
45. WEINBLATT ME: Rheumatoid arthritis: Treat now, not later! (editorial). Ann Intern Med 1996; 124: 773-4.
46. PINCUS T, STEIN CM, WOLFE F: "No evidence of disease" in rheumatoid arthritis using methotrexate in combination with other drugs: A contemporary goal for rheumatology care? Clin Exp Rheumatol 1997; 15: 591-6.
47. PINCUS T, GIBOFSKY A, WEINBLATT ME: Urgent care and tight control of rheumatoid arthritis as in diabetes and hypertension: better treatments but a shortage of rheumatologists. Arthritis Rheum 2002; 46: 851-4.
48. PINCUS T, CALLAHAN LF: The 'side effects' of rheumatoid arthritis: Joint destruction, disability and early mortality. Br J Rheumatol 1993; 32 (Suppl. 1): 28-37.
49. IANNUZZI L, DAWSON N, ZEIN N, KUSHNER I: Does drug therapy slow radiographic deterioration in rheumatoid arthritis? N Engl J Med 1983; 309: 1023-8.
50. KUSHNER I: Does aggressive therapy of rheumatoid arthritis affect outcome (editorial). J Rheumatol 1989; 16: 1-4.
51. PINCUS T, FERRACCIOLI G, SOKKA T et al.: Evidence from clinical trials and long-term observational studies that disease-modifying anti-rheumatic drugs slow radiographic progression in rheumatoid arthritis: updating a 1983 review. Rheumatology 2002; 41: 1346-56.
52. STRAND V, SHARP JT: Radiographic data from recent randomized controlled trials in rheumatoid arthritis: what have we learned? Arthritis Rheum 2003; 48: 21-34.
53. KORPELA M, LAASONEN L, HANNONEN P et al.: Retardation of joint damage in patients with early rheumatoid arthritis by initial aggressive treatment with disease-modifying antirheumatic drugs: five-year experience from the FIN-RACo study. Arthritis Rheum 2004; 50: 2072-81.
54. STRAND V: Long term benefits of treatment by radiographic damage and physical function. Clin Exp Rheumatol 2004; 22 (Suppl. 35): S57-S64.
55. SOKKA T, KAUTIAINEN H, HÄKKINEN K, HANNONEN P: Radiographic progression is getting milder in patients with early rheumatoid arthritis. Results of 3 cohorts over 5 years. J Rheumatol 2004; 31: 1073-82.
56. RAU R, HERBORN G, WASSENBERG S: Healing of erosive changes in rheumatoid arthritis. Clin Exp Rheumatol 2004; 22 (Suppl. 35): S44-S49.
57. SOKKA T, HANNONEN P: Healing of erosions in rheumatoid arthritis. Ann Rheum Dis 2000; 59: 647-9.
58. RAGAN C, FARRINGTON E: The clinical features of rheumatoid arthritis: prognostic indices. JAMA 1962; 181: 663-7.
59. DUTHIE JJR, BROWN PE, TRUELOVE LH, BARAGAR ED, LAWRIE AJ: Course and prognosis in rheumatoid arthritis: a further report. Ann Rheum Dis 1964; 23: 193-204.
60. RASKER JJ, COSH JA: Cause and age at death in a prospective study of 100 patients with rheumatoid arthritis. Ann Rheum Dis 1981; 40: 115-20.
61. RASKER JJ, COSH JA: The natural history of rheumatoid arthritis: a fifteen-year follow-up study. The prognostic significance of features noted in the first year. Clin Rheumatol 1984; 3: 11-20.
62. SCOTT DL, SYMMONS DP, COULTON BL, POPERT AJ: Long-term outcome of treating rheumatoid arthritis: Results after 20 years. Lancet 1987; 16: 1108-11.
63. PINCUS T, CALLAHAN LF: Rheumatology Function Tests: Grip strength, walking time, button test and questionnaires document and predict longterm morbidity and mortality in rheumatoid arthritis. J Rheumatol 1992; 19: 1051-7.
64. PINCUS T, CALLAHAN LF: Prognostic markers of activity and damage in rheumatoid arthritis: Why clinical trials and inception cohort studies indicate more favorable outcomes than studies of patients with established disease. Br J Rheumatol 1995; 34: 196-9.
65. CALLAHAN LF, PINCUS T, HUSTON JW, III, BROOKS RH, NANCE EP Jr, KAYE JJ: Measures of activity and damage in rheumatoid arthritis: Depiction of changes and prediction of mortality over five years. Arthritis Care Res 1997; 10: 381-94.
66. SOKKA T, PINCUS T: Improved outcomes in consecutive patients with rheumatoid arthritis in 2000 compared to 1985, according to an identical cross sectional quantitative standard protocol to evaluate rheumatoid arthritis (SPERA). Arthritis Rheum 2002; 46 (Suppl.): S242.
67. CALLAHAN LF, SMITH WJ, PINCUS T: Self-report questionnaires in five rheumatic diseases: Comparisons of health status constructs and associations with formal education level. Arthritis Care Res 1989; 2: 122-31.
68. PINCUS T, CALLAHAN LF, BROOKS RH, FUCHS HA, OLSEN NJ, KAYE JJ: Self-report questionnaire scores in rheumatoid arthritis compared with traditional physical, radiographic, and laboratory measures. Ann Intern Med 1989; 110: 259-66.
69. MEENAN RF, YELIN EH, NEVITT M, EPSTEIN WV: The impact of chronic disease: a sociomedical profile of rheumatoid arthritis. Arthritis Rheum 1981: 24: 544-9.
70. REISINE ST, GRADY KE, GOODENOW C, FIFIELD J: Work disability among women with rheumatoid arthritis: the relative importance of disease, social, work, and family factors. Arthritis Rheum 1989; 32: 538-43.
71. MAU W, BORNMANN M, WEBER H, WEIDEMANN HF, HECKER H, RASPE HH: Prediction of permanent work disability in a follow-up study of early rheumatoid arthritis: Results of a tree structured analysis using RECPAM. Br J Rheumatol 1996; 35: 652-9.
72. SOKKA T, KAUTIAINEN H, MÖTTÖNEN T, HANNONEN P: Work disability in rheumatoid arthritis 10 years after the diagnosis. J Rheumatol 1999; 26: 1681-5.
73. PUOLAKKA K, KAUTIAINEN H, MOTTONEN T et al.: Impact of initial aggressive drug treatment with a combination of disease-modifying antirheumatic drugs on the development of work disability in early rheumatoid arthritis. A five-year randomized followup trial. Arthritis Rheum 2004; 50: 55-62.
74. PUOLAKKA K, KAUTIAINEN H, MÖTTÖNEN T, HANNONEN P, LEIRISALO-REPO M: Early control of disease activity maintains working capacity in early rheumatoid arthritis. Ann Rheum Dis 2004; 63[S-1], 59.
75. CHUNG C, PINCUS T, SOKKA T: Low rate of work disability in early rheumatoid arthritis in the U.S. at this time. Ann Rheum Dis 2004; 63 [S1]: 196-7.
76. WONG JB: Cost-effectiveness of anti-tumor necrosis factor agents. Clin Exp Rheumatol 2004; 22 (Suppl. 35): S65-S70.
77. COBB S, ANDERSON F, BAUER W: Length of life and cause of death in rheumatoid arthritis. N Engl J Med 1953; 249: 553-6.
78. UDDIN J, KRAUS AS, KELLY HG: Survivorship and death in rheumatoid arthritis. Arthritis Rheum 1970; 13: 125-30.
79. ALLEBECK P, AHLBOM A, ALLANDER E: Increased mortality among persons with rheumatoid arthritis, but where RA does not appear on death certificate: eleven year follow-up of an epidemiological study. Scand J Rheumatol 1981; 10: 301-6.
80. VANDENBROUCKE JP, HAZEVOET HM, CATS A: Survival and cause of death in rheumatoid arthritis: A 25-year prospective followup. J Rheumatol 1984; 11: 158-61.
81. VOLLERTSEN RS, CONN DL, BALLARD DJ, ILSTRUP DM, KAZMAR RE, SILVERFIELD JC: Rheumatoid vasculitis: survival and associated risk factors. Medicine (Baltimore) 1986; 65: 365-75.
82. GORDON DA, STEIN JL, BRODER I: The extra-articular features of rheumatoid arthritis: a systematic analysis of 127 cases. Am J Med 1973; 54: 445-52.
83. LEIGH JP, FRIES JF: Education level and rheumatoid arthritis: evidence from five data centers. J Rheumatol 1991; 18: 24-34.
84. SOKKA T, MÖTTÖNEN T, HANNONEN P: Mortality in early "sawtooth" treated rheumatoid arthritis patients during the first 8- 14 years. Scand J Rheumatol 1999; 28: 282-7.
85. MYLLYKANGAS-LUOSUJÄRVI R, AHO K, ISOMÄKI H: Death attributed to antirheumatic medication in a nationwide series of 1666 patients with rheumatoid arthritis who have died. J Rheumatol 1995; 22: 2214-7.
86. PROUDFIT WL, BRUSCHKE AVG, SONES FM Jr: Natural history of obstructive coronary artery disease: ten-year study of 601 non-surgical cases. Prog Cardiovasc Dis 1978; 21: 53-78.
87. KAPLAN HS: Survival as related to treatment. In KAPLAN HS (Ed.): Hodgkin's Disease. Cambridge, Harvard University Press, 1972: 360-88.
88. PINCUS T, BROOKS RH, CALLAHAN LF: Prediction of long-term mortality in patients with rheumatoid arthritis according to simple questionnaire and joint count measures. Ann Intern Med 1994; 120: 26-34.
89. NEATON JD, WENTWORTH D: Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease. Overall findings and differences by age for 316,099 white men. Arch Intern Med 1992;152: 56-64.
90. KROOT EJA, VAN LEEUWEN MA, VAN RIJSWIJK MH et al.: No increased mortality in patients with rheumatoid arthritis: up to 10 years of follow up from disease onset. Ann Rheum Dis 2000; 59: 954-8.
91. LINDQVIST E, EBERHARDT K: Mortality in rheumatoid arthritis patients with disease onset in the 1980s. Ann Rheum Dis 1999; 58: 11-4.
92. PINCUS T, SOKKA T, WOLFE F: Premature mortality in patients with rheumatoid arthritis: evolving concepts (Editorial). Arthritis Rheum 2001; 44: 1234-6.
93. SOKKA T, HAKKINEN A, KRISHNAN E, HANNONEN P: Similar prediction of mortality by the health assessment questionnaire in patients with rheumatoid arthritis and the general population. Anti Rheum Dis 2004; 63: 494-7.
94. MORELAND LW, BRIDGES SL Jr: Early rheumatoid arthritis: a medical emergency? Am J Med 2001; 111: 498-500.
95. MÖTTÖNEN T, HANNONEN P, KORPELA M et al.: Delay to institution of therapy and induction of remission using single-drug or combination-disease-modifying antirheumatic drug therapy in early rheumatoid arthritis. Arthritis Rheum 2002; 46: 894-8.
96. NELL VP, MACHOLD KP, EBERL G, STAMM TA, UFFMANN M, SMOLEN JS: Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis. Rheumatology 2004; 43:906-14.
97. Veterans Administration Cooperative Study on Antihypertensive Agent: Effects of treatment on morbidity in hypertension: II. Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. JAMA 1970; 213: 1143-50.
98. The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-86.
99. SOKKA T: Work disability in early rheumatoid arthritis. Clin Exp Rheumatol 2003; 21: S71-S74.
100. HALLERT E, HUSBERG M, JONSSON D, SKOGH T: Rheumatoid arthritis is already expensive during the first year of disease (the Swedish TIRA project). Rheumatology 2004; Jul 27 (Epub ahead of print).
101. TOWNSEND JB, SAAG KG: Glucocorticoid use in rheumatoid arthritis: benefits, mechanisms, and risks. Clin Exp Rheumatol 2004; 22 (Suppl. 35): S77-S82.
102. MIKKELSEN WM, DODGE H: A four year follow-up of suspected rheumatoid arthritis: the Tecumseh, Michigan, community health study. Arthritis Rheum 1969; 12: 87-91.
103. O'SULLIVAN JB, CATHCART ES: The prevalence of rheumatoid arthritis: follow-up evaluation of the effect of criteria on rates in Sudbury, Massachusetts. Ann Intern Med 1972; 76: 573-7.
104. ROPES MW, BENNETT GA, COBB S, JACOX RF, JESSAR RA: 1958 revision of diagnostic criteria for rheumatoid arthritis. Bull Rheum Dis 1958; 9: 175-6.
105. LICHTENSTEIN MJ, PINCUS T: Rheumatoid arthritis identified in population based cross sectional studies: Low prevalence of rheumatoid factor. J Rheumatol 1991; 18: 989-93.
106. VALKENBERG HA, BALL J, BURCH TA, BENNETT PH, LAWRENCE JS: Rheumatoid factors in a rural population. Ann Rheum Dis 1966: 25: 497-507.
107. BREMMER JM: Rheumatic complaints in a rural population. Anti Rheum Dis 1961; 20: 149-60.
108. MIKKELSEN WM, DODGE HJ, DUFF IF, KATO H: Estimates of the prevalence of rheumatic diseases in the population of Tecumseh, Michigan, 1959-60. J Chronic Dis 1967; 20: 351-69.
109. ADLER E, ABRAMSON JH, ELKAN Z, BEN HADOR S, GOLDBERG R: Rheumatoid arthritis in a Jerusalem population. 1. Epidemiology of the disease. Am J Epidemiol 1967; 85: 365-77.
110. ADLER E, ABRAMSON JH, GOLDBERG R, ELKAN Z, BEN HADOR S: Rheumatoid arthritis in a Jerusalem population: 2. Epidemiology of rheumatoid factors. Am J Epidemiol 1967; 85: 378-86.
111. BENNETT PH, BURCH TA: The distribution of rheumatoid factor and rheumatoid arthritis in the families of Blackfeet and Pima Indians. Arthritis Rheum 1968; 11: 546-53.
112. BURCH TA, O'BRIEN WM, LAWRENCE JS, BENNETT PH, BUNIM JJ: A comparison of the prevalence of rheumatoid arthritis (RA) and rheumatoid factor (RF) in Indian tribes living in Montana mountains and in Arizona desert. Arthritis Rheum 1963; 6: 765.
113. BURCH TA, O'BRIEN WM: Evaluating diagnostic criteria for rheumatoid arthritis. Milbank Mem Fund Q 1965; 43: 161-71.
114. AHO K, JULKUNEN H, LAINE V, RIPATTI N, WAGER O: Clinical evaluation of the serological tests in rheumatoid arthritis. 1. Normal series collected by random sampling. Acta Rheumatol Scand 1961; 7: 201-8.
115. BAUM J, ZIFF M: Laboratory findings in rheumatoid arthritis. In McCARTY DJ (Ed.): Arthritis and Allied Conditions: A Textbook qf Rheumatology. Philadelphia, Lea & Febiger, 1985: 643-59.
116. HARRISON BJ, SYMMONS DPM, BARRETT EM, SILMAN AJ: The performance of the 1987 ARA classification criteria for rheumatoid arthritis in a population based cohort of patients with early inflammatory polyarthritis. J Rheumatol 1998; 25: 2324-30.
117. VAN AKEN J, VAN BILSEN JHM, ALLAART CF, HUIZINGA TWJ, BREEDVELD FC: The Leiden Early Arthritis Clinic. Clin Exp Rheumatol 2003; 21: S100-S105.
118. VERPOORT KN, VON DONGEN H, ALLAART CF, TOES REM, BREEDVELD FC, HUIZINGA TWJ: Undifferentiated arthritis: disease course assessed in several inception cohorts. Clin Exp Rheumatol 2004; 22 (Suppl. 35): S12-S17.
119. HARRISON BJ, SYMMONS DPM, BRENNAN P, BARRETT EM, SILMAN AJ: Natural remission in inflammatory polyarthritis: issues of definition and prediction. Br J Rheumatol 1996; 35: 1096-100.
120. HARRISON B, SYMMONS DPM, BRENNAN P et al.: Inflammatory polyarthritis in the community is not a benign disease: Predicting functional disability one year after presentation. J Rheumatol 1996; 23: 1326-31.
121. ARNETT FC, EDWORTHY SM, BLOCH DA et al.: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24.
122. PINCUS T, SOKKA T, KAVANAUGH A: Relative versus absolute goals of therapies for rheumatoid arthritis: ACR 20 or ACR 50 responses versus target values for "near remission" of DAS or single measures. Clin Exp Rheumatol 2004; 22 (Suppl. 35): S50-S56.
123. BIEBER J, KAVANAUGH A: Tuberculosis and opportunistic infections: relevance to biologic agents. Clin Exp Rheumatol 2004; 22 (Suppl. 35): S127-S133.
124. ROSS R: Atherosclerosis - an inflammatory disease. N Engl J Med 1999; 340: 115-26.
125. GOODSON N: Coronary artery disease and rheumatoid arthritis. Curr Opin Rheumatol 2002; 14: 115-20.
126. FRIEDMAN LM, FURBERG CD, DeMETS DL: Fundamentals of Clinical Trials. 1st ed., Littleton, John Wright - PSG Inc., 1984: 1-225.
127. FEINSTEIN AR: An additional basic science for clinical medicine. II. The limitations of randomized trials. Ann Intern Med 1983; 99: 544-50.
128. SACKETT DL, ROSENBERG WM, GRAY JM, HAYNES RB, RICHARDSON WS: Evidence based medicine: what it is and what it isn't. It's about integrating individual clinical expertise and the best external evidence. Br Med J 1996; 312: 71-2.
129. FREIMAN JA, CHALMERS TC, SMITH H Jr, KUEBLER RR: The importance of beta, the type II error and sample size in the design and interpretation of the randomized control trial: survey of 71 " negative" trials. N Engl J Med 1978; 299: 690-4.
130. SACKETT DL, GENT M: Controversy in counting and attributing events in clinical trials. N Engl J Med 1979; 301: 1410-2.
131. SACKETT DL: The competing objectives of randomized trials. N Engl J Med 1980; 303: 1059-60.
132. HUSKISSON EC: Important factors in the success and failure of clinical trials (closing remarks). Agents Actions 1980; 7 (Suppl.): 323-4.
133. FREIREICH EJ: The randomized clinical trial as an obstacle to clinical research. In VARCO RL and DELANEY JP (Eds.): Controversy in Surgery. Philadelphia, W.B. Saunders, 1983: 5-12.
134. DIAMOND GA, FORRESTER JS: Clinical trials and statistical verdicts: Probable grounds for appeal. Ann Intern Med 1983; 98: 385-94.
135. CHALMERS TC, CELANO P, SACKS HS, SMITH H Jr: Bias in treatment assignment in controlled clinical trials. N Engl J Med 1983; 309: 1358-61.
136. BOMBARDIER C, TUGWELL P: Controversies in the analysis of longterm clinical trials of slow acting drugs (editorial). J Rheumatol 1985; 12: 403-5.
137. GUYATT G, SACKETT D, TAYLOR DW, CHONG J, ROBERTS R, PUGSLEY S: Determining optimal therapy - randomized trials in individual patients. N Engl J Med 1986; 314: 889-92.
138. HAWLEY DJ, WOLFE F: Are the results of controlled clinical trials and observational studies of second line therapy in rheumatoid arthritis valid and generalizable as measures of rheumatoid arthritis outcome: analysis of 122 studies. J Rheumatol 1991; 18: 1008-1014.
139. FELSON DT, ANDERSON JJ, MEENAN RF: Time for changes in the design, analysis, and reporting of rheumatoid arthritis clinical trials. Arthritis Rheum 1990; 33: 140-9.
140. GOTZSCHE PC: Methodology and overt and hidden bias in reports of 196 double-blind trials of nonsteroidal antiinflammatory drugs in rheumatoid arthritis. Controlled Clin Trials 1989; 10: 31-56.
141. ROTHWELL PM: Can overall results of clinical trials be applied to all patients? Lancet 1995; 345: 1616-9.
142. FEINSTEIN AR, HORWITZ RI: Problems in the "evidence" of "evidence-based medicine". Am J Med 1997; 103: 529-35.
143. HORWITZ RI: Clinical versus statistical considerations in the design and analysis of clinical research. J Clin Epidemiol 1998; 51: 305-7.
144. CONCATO J, SHAH N, HORWITZ RI: Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med 2000; 342: 1887-92.
145. PINCUS T: Rheumatoid arthritis: disappointing long-term outcomes despite successful short-term clinical trials. J Clin Epidemiol 1988; 41: 1037-41.
146. PINCUS T: Limitations of randomized controlled clinical trials to recognize possible advantages of combination therapies in rheumatic diseases. Semin Arthritis Rheum 1993; 23 (Suppl. 1): 2-10.
147. PINCUS T, STEIN M: What is the best source of useful data on the treatment of rheumatoid arthritis: Clinical trials, clinical observations, or clinical protocols? J Rheumatol 1995; 22: 1611-7.
148. PINCUS T: Analyzing long-term outcomes of clinical care without randomized controlled clinical trials: The consecutive patient questionnaire database. Advances 1997; 13: 3-32.
149. PINCUS T, STEIN CM: Why randomized controlled clinical trials do not depict accurately long-term outcomes in rheumatoid arthritis: Some explanations and suggestions for future studies. Clin Exp Rheumatol 1997; 15 (Suppl. 17): S27-S38.
150. SHORT CL, BAUER W: The course of rheumatoid arthritis in patients receiving simple medical and orthopedic measures. N Engl J Med 1948; 238: 142-8.
151. LUUKKAINEN R, KAJANDER A, ISOMÄKI H: Treatment of rheumatoid arthritis (letter). Br Med J 1978; 2: 1501.
152. PINCUS T, SOKKA T, KAVANAUGH A: Quantitative documentation of risk/benefit of new therapies for rheumatoid arthritis: patient questionnaires as an optimal measure in standard care. Clin Exp Rheumatol 2004; 22 (Suppl. 35): S26-S33.
153. WOLFE F, MICHAUD K: The clinical and research significance of the erythrocyte sedimentation rate. J Rheumatol 1994; 21: 1227-37.
154. SOKKA T, PINCUS T: Most patients receiving routine care for rheumatoid arthritis in 2001 did not meet inclusion criteria for most recent clinical trials or American College of Rheumatology criteria for remission. J Rheumatol 2003; 30: 1138-46.
155. WOLFE F, HAWLEY DJ: Remission in rheumatoid arthritis. J Rheumatol 1985; 12: 245-52.
156. YAZICI Y, SOKKA T, KAUTIAINEN H, SWEARINGEN C, KULMAN I, PINCUS T: Long-term safety of methotrexate in routine clinical care: discontinuation is unusual and rarely due to laboratory abnormalities. Ann Rheum Dis 2004; Jun 18 (Epub ahead of print).
157. MONSON RR, HALL AP: Mortality among arthritics. J Chron Dis 1976; 29: 459-67.
158. LEWIS P, HAZLEMAN BE, HANKA R, ROBERTS S: Cause of death in patients with rheumatoid arthritis with particular reference to azathioprine. Ann Rheum Dis 1980; 39: 457-61.
159. PRIOR P, SYMMONS DPM, SCOTT DL, BROWN R, HAWKINS CF: Cause of death in rheumatoid arthritis. Br J Rheumatol 1984; 23: 92-9.